 |
Research/Clinical Trials
Sponsor: NTI Inc.
Study: NTI 0303:Patients with Peritumoral brain edema with malignant brain tumors
PI: Laszlo Mechtler, M. D.
Description: A Phase III Randomized, Double-Blind Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated with Peritumoral Brain Edema in Patients with Malignant Brain Tumors who Require Chronic Administration of High-Dose Dexamethasone - 27 Patients - Highest Enrollment in the world enrolling 40% of all patients!!
Sponsor: NTI Inc.
Study: NTI 0302: Patients with Peritumoral brain edema with malignant brain tumors
PI: Laszlo Mechtler, M. D.
Description: A Phase III Randomized, Double-Blind Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated with Peritumoral Brain Edema in Patients with Primary Malignant Gliomas - 4 patients
Sponsor: NTI Inc.
Study: NTI 0501:Patients with Peritumoral brain edema with malignant brain tumors
PI: Laszlo Mechtler, M. D.
Description: An Open Label, Extended- Use Study of Human Corticotrophin- Releasing Factor (hCRF) Intended For Patients Who Participate In The Dexamethasone- Sparing studies NTI 0303 and 0302 - 14 Patients
Sponsor: Celldex Therapeutics
Study: CDX-110
PI: Laszlo Mechtler, M. D.
Description: A Phase II/III Randomized Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme - August 2007
Sponsor: Eli Lilly and Company
Study: H6Q-MC-JCBF
PI: Laszlo Mechtler, M. D.
Description: A Randomized Phase 3 Study f Enzastaurin HCI versus Lomustine in the treatment of Recurrent, Intracranial Glioblastoma Multiforme - 4 patients
|
|
Roswell Park Studies
Sponsor: Investigator initiated Schering Plough Study.
Study: RPC 0206
PI: Laszlo Mechtler, M. D.
Description: A Phase II Study of Gammaknife Radiosurgery and Temozolomide for Patients with 1-4 Unresected Brain Metastases -
1 Patient
Study: NCG 13403: RTOG 0211
Description: Phase I/III randomized study of radiation therapy and Temozolomide versus radiation therapy and BCNU for Anaplastic Astrocytoma.
Study: NCG 52005: RTOG 0424
Description: Phase II randomized study of Temozolomide based chemoradiotherapy regimen for high-risk low-grade gliomas.
Study: NCG 74906: RTOG 0525
Description: Phase III trail comparing conventional adjuvant Temozolomide with dose intensive Temozolomide in patients with newly diagnosed Glioblastoma.
Study: PH 33004
Description: Phase II Multi-center study of intratumoral/ interstitial therapy with TransMID compared to best standard of care in patients with progressive and or recurrent, non- resectable Glioblastoma multiforme.
|
|
